Novo Nordisk shares fell after its experimental medicine, ziltivekimab, failed to show a statistically meaningful reduction in major adverse cardiovascular events in patients with certain diseases.
Novo Nordisk shareholders allege the company misled investors about a key clinical trial for its next-generation weight-loss drug CagriSema. A U.S. judge on Tuesday allowed parts of that lawsuit to move forward.
A U.S. judge said on Tuesday that Novo Nordisk must face part of a lawsuit accusing it of defrauding shareholders about a clinical trial for its weight loss and diabetes treatment CagriSema.